報價延遲最少15分鐘:2025/09/04 07:52 EDT
盤前時段
|
||||
|
1.42 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.43
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.69/-0.21
|
|
企業價值
22.50M
|
| 資產負債 |
|
每股賬面淨值
0.55
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/09/04 07:52 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in theapplication of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing. |
